Category: TCTMD Articles

Betrixaban Approved for Prevention of VTE

June 23, 2017

“The US Food and Drug Administration (FDA) has approved betrixaban (Bevyxxa, Portola Pharmaceuticals), an oral factor Xa inhibitor administered once daily, for the prevention of thromboembolic complications in patients hospitalized for acute medical illness who are at risk for venous thromboembolism (VTE) due to restricted mobility and other risk factors.”

Visit Website
Page 90 of 98«...5101520253035404550...8889909192...95...»